里昂:维持海吉亚医疗、锦欣生殖评级“跑赢大市” 目标价亦均下调

新浪网
10 Feb

里昂发布研究报告称,预计海吉亚医疗在2024年至2026年间,公司收入及纯利的年均复合增长率分别达12%及13%,主要受到现有医院的自然增长推动,将目标价由29.9港元降至20.1港元,维持评级“跑赢大市”。该行表示,将海吉亚医疗今明两年收入预测下调2%至7%,以及纯利预测降2%至8%,主要因为预料未来三年都没有进一步的并购,而在2021至2023年间平均每年收购两至三家医院。此外,该行将锦欣生殖...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10